Cargando…
Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen
Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harboring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistan...
Autores principales: | Goh, Corinna Jie Hui, Wong, Jin Huei, El Farran, Chadi, Tan, Ban Xiong, Coffill, Cynthia R, Loh, Yuin-Hain, Lane, David, Arumugam, Prakash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022920/ https://www.ncbi.nlm.nih.gov/pubmed/33604667 http://dx.doi.org/10.1093/g3journal/jkaa069 |
Ejemplares similares
-
Correction to: Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen
por: Goh, Corinna Jie Hui, et al.
Publicado: (2022) -
CRISPR/Cas9-Mediated Genome Editing and Mutagenesis of EcChi4 in Exopalaemon carinicauda
por: Gui, Tianshu, et al.
Publicado: (2016) -
Site-Directed Genome Knockout in Chicken Cell Line and Embryos Can Use CRISPR/Cas Gene Editing Technology
por: Zuo, Qisheng, et al.
Publicado: (2016) -
A Method for Rapid Selection of Randomly Induced Mutations in a Gene of Interest Using CRISPR/Cas9 Mediated Activation of Gene Expression
por: Ng, William A., et al.
Publicado: (2020) -
CRISPR screen identifies CEBPB as contributor to dyskeratosis congenita fibroblast senescence via augmented inflammatory gene response
por: Westin, Erik R, et al.
Publicado: (2023)